What is the translation of " DELOVANJEM JETER " in English?

• hepatic function
• liver function

Examples of using Delovanjem jeter in Slovenian and their translations into English

Bolniki z okvarjenim delovanjem jeter.
Patients with impairment of liver function.

Zaradi omejenih izkušenj učinkovitosti in varnosti Dynepa ni mogoče oceniti pri bolnikih z okvarjenim delovanjem jeter.
Due to limited experience, the efficacy and safety of Dynepo could not be assessed in patients with impaired liver function.

Bolniki z okvarjenim delovanjem jeter ali ledvic.
Patients with impaired hepatic or renal function.

Če imate ali ste imeli hude težave z nepravilnim delovanjem jeter.
Have or have had severe problems with your liver not working properly.

Pri bolnikih z blago do zmerno okvarjenim delovanjem jeter je treba biti previden in nadzorovati je treba delovanje jeter..
In patients with mild to moderate hepatic impairment, caution should be exercised and monitoring of liver function should be performed.

Sledijo slabost, bruhanje in driska, skupaj z zmanjšanim delovanjem jeter in ledvic.
Vomiting, diarrhea and rash usually follow, along with decreased function of the liver and kidneys.

Vročina, otekanje udov, občutek bolanosti, težave z delovanjem jeter(razvidno iz krvnih preiskav) in povečan krvni bilorubin(ki ga izločajo jetra)..
Fever, swelling in the limbs, feeling ill problems with liver function(seen in blood tests) and increased blood bilirubin(excreted by the liver)..

Zdravilo Repso je kontraindicirano pri bolnikih s hudo hipoproteinemijo ali okvarjenim delovanjem jeter(glejte poglavje 4.3).
Repso is contraindicated in patients with severe hypoproteinaemia or impairment of liver function(see section 4.3).

Vročina, zatekanje v okončinah, slabo počutje težave z delovanjem jeter(vidno v krvnih testih) in povečanje bilirubina v krvi(izločenega iz jeter)..
Fever, swelling in the limbs, feeling ill problems with liver function(seen in blood tests) and increased blood bilirubin(excreted by the liver)..

V drugem preskušanju so farmakokinetiko abiraterona raziskovali pri bolnikih z obstoječo hudo okvaro jeter(n=8)(Child-Pugh razred C) in pri 8 kontrolnih zdravih preiskovancih z normalnim delovanjem jeter.
In another trial, the pharmacokinetics of abiraterone were examined in subjects with pre-existing severe(n= 8) hepatic impairment(Child-Pugh Class C) and in 8 healthy control subjects with normal hepatic function.

Izkušenj z uporabo atosibana pri bolnicah z okvarjenim delovanjem jeter ali ledvic ni(glejte poglavje 4. 2 in 4. 4).
There is no experience with atosiban treatment in patients with impaired function of the liver or kidneys(see sections 4.2 and 4.4).

Sistemska izpostavljenost trastuzumabu emtanzinu(AUC) v 1. ciklusu je bila pri bolnikih z blago jetrno okvaro približno 38%, pri bolnikih z zmerno jetrno okvaro pa 67% nižja kot pri bolnikih z normalnim delovanjem jeter.
Systemic exposures(AUC) of trastuzumab emtansine at Cycle 1 in patients with mild and moderate hepatic impairment were approximately 38% and 67% lower than that of patients with normal hepatic function.

Z zdravljenjem z atosibanom ni izkušenj pri bolnicah z okvarjenim delovanjem jeter ali ledvic(glejte poglavji 4. 2 in 5. 2).
There is no experience with atosiban treatment in patients with impaired function of the liver or kidneys(see sections 4.2 and 5.2).

Če ima vaš otrok zmerne ali hude težave z delovanjem jeter, bo otrokov zdravnik mogoče moral zmanjšati odmerek zdravila Kalydeco, ker jetra vašega otroka ne čistijo ivakaftorja iz krvi tako hitro kot pri otrocih, ki imajo normalno delovanje jeter..
If your child has moderate or severe problems with liver function, your child's doctor may need to reduce the dose of Kalydeco, as your child's liver is not clearing ivacaftor as fast as in children who have normal liver function..

Zdravilo Zepatier se ne sme uporabljati pri bolnikih z zmerno ali močno zmanjšanim delovanjem jeter(cirozo razreda B ali C po Child-Pughu).
Zepatier must not be used in patients with moderately or severely reduced liver function(Child-Pugh class B or C cirrhosis).

Zdravilo Adempas se ne sme uporabljati pri bolnikih z močno zmanjšanim delovanjem jeter, pri bolnikih, ki imajo pred začetkom zdravljenja sistolični krvni tlak(krvni tlak, ki nastane, ko se srce skrči) nižji od 95 mmHg, in med nosečnostjo.
Adempas must not be used in patients with severely reduced liver function, with systolic blood pressure(blood pressure when the heart is contracting) below 95 mmHg before starting treatment, or during pregnancy.

Lahko je akutna pljučna insuficienca, vnetje in okužba blage geneze, težave z delovanjem jeter, srca in drugih notranjih organov.
It can be acute pulmonary insufficiency, inflammation and infection of mild genesis, problems with the function of the liver, heart and other internal organs.

Med bolniki z blago okvaro jeter in bolniki z normalnim delovanjem jeter ni bilo klinično pomembnih razlik v očistku pembrolizumaba.
No clinically important differences in the clearance of pembrolizumab were found between patients with mild hepatic impairment and normal hepatic function.

Zaradi omejenih izkušenj učinkovitosti in varnosti epoetina theta ni bilo mogoče oceniti pri bolnikih z oslabljenim delovanjem jeter ali homozigotno anemijo srpastih celic.
Due to limited experience, the efficacy and safety of epoetin theta could not be assessed in patients with impaired liver function or homozygous sickle cell anaemia.

Z razvojem patoloških stanj, povezanih z okvarjenim delovanjem jeter, morate nemudoma obiskati specialist in dobiti kvalificirano pomoč.
With the development of pathological conditions associated with impaired activity of the liver, you must immediately visit a specialist and get qualified help.

Ne uporabite pri živalih z boleznimi prebavil, kot so draženje in krvavitve, okvarjenim delovanjem jeter, srca ali ledvic in hemoragičnimi boleznimi.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

V odprti študiji večanja odmerka 1. faze pri 110 bolnikih z napredovalimi malignimi tumorji in bodisi normalnim bodisi okvarjenim delovanjem jeter so bile koncentracije temsirolimusa in njegovega presnovka sirolimusa povečane pri bolnikih s povečanimi ravnmi aspartat-aminotransferaze(AST) ali bilirubina.
In an open-label, dose-escalation Phase 1 study in 110 subjects with advanced malignancies and either normal or impaired hepatic function, concentrations of temsirolimus and its metabolite sirolimus were increased in patients with elevated aspartate aminotransferase(AST) or bilirubin levels.

Zaradi omejenih izkušenj učinkovitosti in varnosti zdravila Lantus ni bilo mogoče oceniti pri bolnikih z okvarjenim delovanjem jeter in bolnikih z zmerno ali hudo okvaro ledvic(glejte poglavje 4. 4).
Due to limited experience the efficacy and safety of Lantus could not be assessed in the following groups of patients: patients with impaired liver function or patients with moderate/ severe renal impairment(see section 4.4).